Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PRPO 
Precipio Inc (PRPO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PRPO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -25.75% | Avg. Invested days 36 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.89M USD | Price to earnings Ratio - | 1Y Target Price 19 |
Price to earnings Ratio - | 1Y Target Price 19 | ||
Volume (30-day avg) 11573 | Beta 1.42 | 52 Weeks Range 4.31 - 10.74 | Updated Date 03/30/2025 |
52 Weeks Range 4.31 - 10.74 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin -22.9% | Operating Margin (TTM) -27.22% |
Management Effectiveness
Return on Assets (TTM) -18.98% | Return on Equity (TTM) -29.22% |
Valuation
Trailing PE - | Forward PE 15.43 | Enterprise Value 9521227 | Price to Sales(TTM) 0.53 |
Enterprise Value 9521227 | Price to Sales(TTM) 0.53 | ||
Enterprise Value to Revenue 0.55 | Enterprise Value to EBITDA -1.15 | Shares Outstanding 1482330 | Shares Floating 1306100 |
Shares Outstanding 1482330 | Shares Floating 1306100 | ||
Percent Insiders 12.99 | Percent Institutions 8.79 |
Analyst Ratings
Rating 5 | Target Price 40 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Precipio Inc
Company Overview
History and Background
Precipio, Inc. was founded in 2011. It focuses on cancer diagnostics and aims to improve diagnostic accuracy and efficiency. It has evolved from a technology licensing company to a provider of diagnostic services and products.
Core Business Areas
- HemeScreen: A comprehensive hematopathology testing service, providing diagnostic and prognostic information for hematological malignancies.
- IV Cell: A cell culture media designed to improve the viability and growth of cells used in cell-based assays.
- ICE Cold PCR: A patented PCR technology aimed at enhancing the detection of rare mutations.
Leadership and Structure
Ilyas Rafiq is the CEO. The company has a board of directors and a management team overseeing various departments, including research, development, sales, and marketing.
Top Products and Market Share
Key Offerings
- HemeScreen: Comprehensive hematopathology testing service. Market share data is not readily available. Competitors include NeoGenomics (NEO) and LabCorp (LH).
- IV Cell: Cell culture media for improved cell viability. Market share data is not readily available. Competitors include Thermo Fisher Scientific (TMO) and Corning (GLW).
- ICE Cold PCR: PCR technology for detecting rare mutations. Market share data is not readily available. Competitors include Roche (RHHBY) and Qiagen (QGEN).
Market Dynamics
Industry Overview
The cancer diagnostics market is growing, driven by advancements in technology and the increasing prevalence of cancer. Personalized medicine and targeted therapies are key trends.
Positioning
Precipio is positioned as a provider of specialized diagnostic solutions, particularly in hematopathology. Its competitive advantages lie in its proprietary technologies like ICE Cold PCR.
Total Addressable Market (TAM)
The global cancer diagnostics market is estimated to be worth hundreds of billions of dollars. Precipio is positioned to capture a portion of this market through its specialized offerings.
Upturn SWOT Analysis
Strengths
- Proprietary technologies (e.g., ICE Cold PCR)
- Specialized expertise in hematopathology
- Comprehensive diagnostic solutions
Weaknesses
- Limited financial resources
- Small market share compared to larger competitors
- Dependence on key personnel
Opportunities
- Expanding adoption of personalized medicine
- Partnerships with pharmaceutical companies
- Growing demand for accurate cancer diagnostics
Threats
- Competition from larger diagnostic companies
- Regulatory changes
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- NEO
- LH
- TMO
- QGEN
Competitive Landscape
Precipio faces intense competition from larger, more established diagnostic companies. Its competitive advantage lies in specialized technologies and focused expertise, but its limited resources pose a challenge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, with fluctuations in revenue and profitability.
Future Projections: Future growth projections are uncertain and dependent on successful commercialization of their technologies and market adoption.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, developing new diagnostic assays, and pursuing partnerships.
Summary
Precipio Inc. is a small company specializing in cancer diagnostics, particularly hematopathology. They have proprietary technologies like ICE Cold PCR that can give them an edge. Financial constraints and stiff competition from bigger players like NeoGenomics and LabCorp are areas to watch out for. Future growth will depend on successful commercialization and strategic partnerships.
Similar Companies
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
NEO
NeoGenomics Inc
NEO
NeoGenomics Inc
QGEN
Qiagen NV
QGEN
Qiagen NV
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Yahoo Finance
- Company Filings
- Market Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Precipio Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2000-07-18 | Founder, President, CEO & Director Mr. Ilan Danieli | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 51 | Website https://www.precipiodx.com |
Full time employees 51 | Website https://www.precipiodx.com | ||
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.